A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors

2024-516331-27-00 Protocol KN-8701/KIN2787CI101 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 10 Jun 2022 · Status Ongoing, recruiting · 4 EU/EEA countries · 27 sites · Protocol KN-8701/KIN2787CI101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 503
Countries 4
Sites 27

Participants with BRAF and/or NRAS mutation positive tumors

Key facts

Sponsor
Pierre Fabre Medicament
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
10 Jun 2022 → ongoing
Decision date (initial)
2024-10-18
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516331-27-00
EudraCT number
2021-005389-16
ClinicalTrials.gov
NCT04913285

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Participants with BRAF and/or NRAS mutation positive tumors

VersionLevelCodeTermSystem organ class
20.0 SOC 10029104 Neoplasms benign malignant and unspecified (incl cysts and polyps) 2
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Pierre Fabre Medicament

Sponsor organisation
Pierre Fabre Medicament
Address
Les Cauquillous
City
Lavaur
Postcode
81500
Country
France

Scientific contact point

Organisation
Pierre Fabre Medicament
Contact name
Corporate Scientific and Medical

Public contact point

Organisation
Pierre Fabre Medicament
Contact name
Corporate Scientific and Medical

Locations

4 EU/EEA countries · 27 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 106 12
Germany Authorised, recruitment pending 18 3
Italy Ongoing, recruiting 12 2
Spain Ongoing, recruiting 46 10
Rest of world
Australia, China, United States, Switzerland, Taiwan
321

Investigational sites

France

12 sites · Ongoing, recruiting
Oncopole Claudius Regaud
Oncology Department, 1 Avenue Irene Joliot Curie, 31100, Toulouse
Centre Hospitalier Universitaire De Poitiers
Oncology Department, 2 Rue De La Miletrie, 86000, Poitiers
Hospices Civils De Lyon
Oncology Department, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite
Institut Bergonie
Medical Oncology, 180 R De Saint Genes, 229 Cours De L Argonne, Bordeaux
Centre Hospitalier Universitaire De Nice
Oncology, 151 Route De Saint Antoine, 06200, Nice
Centre Francois Baclesse
Oncology Department, 3 Avenue Du General Harris, Cs 45026, Caen Cedex 5
Centre Leon Berard
Medical Oncology, 28 Rue Laennec, 69008, Lyon
Institut Gustave Roussy
Oncology, 114 Rue Edouard Vaillant, 94800, Villejuif
Assistance Publique Hopitaux De Paris
Oncology Department, 1 Avenue Claude Vellefaux, 75010, Paris
Centre Hospitalier Regional De Marseille
Oncology Department, 264 Rue Saint Pierre, 13005, Marseille
Centre Hospitalier Universitaire De Lille
Oncology Department, Boulevard Du Professeur Jules Leclercq, 59000, Lille
Centre Hospitalier Universitaire De Nantes
Medical Oncology, Boulevard Du Professeur Jacques Monod, 44800, Saint Herblain

Germany

3 sites · Authorised, recruitment pending
Elbe Kliniken Stade-Buxtehude gGmbH
Dermatology, Am Krankenhaus 1, 21614, Buxtehude
University Medical Center Hamburg-Eppendorf
Dermatology, Martinistrasse 52, Eppendorf, Hamburg
Universitaetsklinikum Essen AöR
Dermatology, Hufelandstrasse 55, Holsterhausen, Essen

Italy

2 sites · Ongoing, recruiting
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Medical Oncology, Via Mariano Semmola 52, 80131, Naples
Fondazione IRCCS Istituto Nazionale Dei Tumori
Medical Oncology, Via Giacomo Venezian 1, 20133, Milan

Spain

10 sites · Ongoing, recruiting
Hospital Clinico Universitario De Valencia
Medical Oncology, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitario Hm Sanchinarro
Oncology Department, Calle Ona 10, 28050, Madrid
Hospital General Universitario Gregorio Maranon
Medical Oncology, Calle Del Doctor Esquerdo 46, 28009, Madrid
Hospital General Universitario De Valencia
Oncology Department, Avenida Del Tres Cruces 2, 46014, Valencia
Complejo Hospitalario Universitario Insular Materno Infantil
Medical Oncology, Autovia Del Sur S/n, 35017, Las Palmas De Gran Canaria
Hospital Clinic De Barcelona
Oncology Department, Calle Villarroel 170, 08036, Barcelona
Hospital Universitario Regional De Malaga
Oncology Department, Avenida De Carlos De Haya S/N, 29010, Malaga
Hospital Universitari Dexeus Grupo Quironsalud
Oncology Department, Calle De Sabino Arana 5-19, 08028, Barcelona
Hospital Universitario Virgen De La Macarena
Oncology Department, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Hospital Universitario Quironsalud Madrid
Oncology Department, Calle De Diego De Velazquez 1, 28223, Pozuelo De Alarcon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2022-06-22 2022-08-09
Italy 2025-10-10 2025-10-22
Spain 2022-06-10 2022-06-20

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-10-02 Spain Acceptable
2024-10-15
2024-10-15
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-02 Spain Acceptable
2025-01-21
2025-01-22
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-17 Spain Acceptable 2025-03-25
4 SUBSTANTIAL MODIFICATION SM-3 2025-02-17 Acceptable 2025-04-22
5 SUBSEQUENT ADDITION OF MSC APP-5 2025-04-11 Acceptable
2025-01-21
2025-06-17
6 SUBSTANTIAL MODIFICATION SM-4 2025-07-23 Spain Acceptable
2025-09-17
2025-09-18
7 SUBSEQUENT ADDITION OF MSC APP-7 2025-10-22 Acceptable
2025-09-17
2025-12-22
8 SUBSTANTIAL MODIFICATION SM-5 2026-02-18 Spain Acceptable 2026-04-08